Comparative Pharmacology
Head-to-head clinical analysis: DEPAKENE versus PREGABALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPAKENE versus PREGABALIN.
DEPAKENE vs PREGABALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels; also modulates histone deacetylase activity.
Binds to the alpha2-delta subunit of voltage-gated calcium channels, reducing calcium influx and decreasing release of excitatory neurotransmitters (e.g., glutamate, norepinephrine, substance P).
Oral: Initial 15 mg/kg/day divided into 1-3 doses, increase by 5-10 mg/kg/day weekly; typical maintenance 30-60 mg/kg/day. Intravenous: Same total daily dose as oral, administered as continuous infusion or divided q6h.
Initial: 75 mg orally twice daily; may increase to 150 mg twice daily within 1 week; maximum: 600 mg/day in divided doses.
None Documented
None Documented
Clinical Note
moderatePregabalin + Fluticasone propionate
"The therapeutic efficacy of Fluticasone propionate can be increased when used in combination with Pregabalin."
Clinical Note
moderatePregabalin + Haloperidol
"The therapeutic efficacy of Haloperidol can be increased when used in combination with Pregabalin."
Clinical Note
moderatePregabalin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Pregabalin."
Clinical Note
moderatePregabalin + Fluconazole
10-16 hours (monotherapy); 5-9 hours in patients on enzyme-inducing co-medications; prolonged in hepatic impairment (up to 30 hours) or neonates.
Terminal elimination half-life is approximately 6.3 hours. In patients with renal impairment, half-life is prolonged (up to 48 hours in anuria). Requires dose adjustment based on creatinine clearance.
Renal: <3% unchanged; primarily hepatic metabolism via glucuronidation (50%) and beta-oxidation (40%), with metabolites excreted renally. Fecal: negligible.
Primarily renal excretion as unchanged drug (92-99% of dose). Approximately 0.1% is metabolized. No biliary or fecal elimination of significance.
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The serum concentration of Fluconazole can be increased when it is combined with Pregabalin."